---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-018242"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-05-22T20:00:36+00:00"
generated_at: "2026-05-22T21:34:51.563555+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech ASCO abstract on Annamycin cardiac safety shows no cardiotoxicity in 90 patients

## Summary
- Abstract accepted for poster at 2026 ASCO Annual Meeting (May 29–June 2, Chicago).
- Pooled safety analysis of 90 Annamycin patients; median cumulative dose 660 mg/m2.
- No significant LVEF change from baseline (mean diff -0.12%, p=0.84); no dose correlation.
- CEO highlights potential to provide anthracycline therapy without cardiotoxicity limits.
- Company's Phase 1b/2 AML study previously showed 50% CR and median OS of 12.39 months.

## SEC filing metadata
- accession: 0001437749-26-018242
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-05-22T20:00:36+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926018242/0001437749-26-018242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926018242/mbrx20260522_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-018242
- JSON: https://secwatch.observer/filing/0001437749-26-018242.json
- Plain text: https://secwatch.observer/filing/0001437749-26-018242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.